Table 3.

Association of baseline atenolol with fall, syncope, orthostatic hypotension, or a composite outcome during the trial period in strata of drug assignment or overall, HR (95% CI)

Outcome			Unadjusted		Age/Sex/Race Adjusted
	Did not use atenolol	Used atenolol
Falls	Events/Total	Events/Total	HR (95% CI)	P	HR (95% CI)	P
Amlodipine	84/6293	1/229	0.36 (0.05–2.56)	0.31	0.37 (0.05–2.68)	0.33
Chlorthalidone	111/10563	2/437	0.46 (0.11–1.84)	0.27	0.45 (0.11–1.83)	0.27
Lisinopril	66/6180	3/262	1.13 (0.35–3.59)	0.84	1.06 (0.33–3.39)	0.92
Overall	261/23036	6/928	0.60 (0.27–1.36)	0.22	0.60 (0.27–1.35)	0.22
Syncope
Amlodipine	194/6293	5/229	0.78 (0.32–1.89)	0.58	0.89 (0.36–2.16)	0.79
Chlorthalidone	334/10563	11/437	0.85 (0.47–1.55)	0.59	0.92 (0.50–1.67)	0.78
Lisinopril	198/6180	13/262	1.61 (0.92–2.82)	0.10	1.65 (0.94–2.90)	0.08
Overall	726/23036	29/928	1.06 (0.73–1.53)	0.77	1.14 (0.79–1.66)	0.48
Orthostatic hypotension
Amlodipine	62/6293	4/229	2.01 (0.73–5.52)	0.18	1.99 (0.72–5.51)	0.19
Chlorthalidone	103/10563	7/437	1.75 (0.81–3.77)	0.15	1.81 (0.84–3.92)	0.13
Lisinopril	73/6180	0/262	-		-
Overall	238/23036	11/928	1.22 (0.67–2.34)	0.51	1.27 (0.69–2.33)	0.44
Composite
Amlodipine	306/6293	8/229	0.78 (0.39–1.57)	0.49	0.86 (0.42–1.73)	0.67
Chlorthalidone	501/10563	19/437	0.97 (0.61–1.54)	0.90	1.02 (0.65–1.62)	0.92
Lisinopril	307/6180	16/262	1.29 (0.78–2.13)	0.33	1.30 (0.78–2.15)	0.31
Overall	1114/23036	43/928	1.02 (0.75–1.38)	0.913	1.07 (0.79–1.46)	0.65